These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://deborahzkki436957.blog-ezine.com/39489175/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide